[Hemosiderosis in Chronic Hepatitis C: Should Venesection Precede Treatment with Interferon-alpha and Ribavirin?].
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001815:Bloodletting; D003131:Combined Modality Therapy; D005260:Female; D000071020:Hemochromatosis Protein; D006486:Hemosiderosis / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics; D006509:Hepatitis B / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D009154:Mutation; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*
D000998:Antiviral Agents; C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D016898:Interferon-alpha; D008565:Membrane Proteins; D012254:Ribavirin
Hämosiderose bei chronischer Hepatitis C: Aderlässe vor Therapie mit Interferon-alpha und Ribavirin?